In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4222-4223

  Werngren, Jim ^a   Wijkander, Maria ^a   Perskvist, Nasrin ^b   Balasubramanian, V ^c,e   Sambandamurthy, Vasan K ^c   Rodrigues, Camilla ^d   Hoffner, Sven ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d P D HINDUJA NATIONAL HOSPITAL   (India)

^e Philips Electronics India Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 5847; LINEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; OXAZOLIDINONE DERIVATIVE; POSIZOLID;

ABSCESS; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CROSS RESISTANCE; FECES; HUMAN; IN VITRO STUDY; LUNG BIOPSY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PLEURA FLUID; PRIORITY JOURNAL; SPUTUM; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TUBERCULOSIS, PULMONARY;

EID: 84903158717     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02718-14     Document Type: Article

References (11)

1. World Health Organization. 2013. Global tuberculosis report 2013. Report WHO/HTM/TB/2013.11. World Health Organization, Geneva, Switzerland.
2. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12: 388-404. http://dx.doi.org/10.1038/nrd4001.
3. Palomino JC, Martin A. 2013. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol. 8:1071-1080. http://dx.doi.org/10.2217/fmb.13.85.
4. Sacksteder KA, Protopopova M, Barry CE, III, Andries K, Nacy CA. 2012. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 7:823-837. http://dx.doi.org/10.2217/fmb. 12.56.
5. Dawson R, Diacon A. 2013. PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert Opin. Investig. Drugs 22: 927-932. http://dx.doi.org/10.1517/13543784.2013.801958.
6. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD. 2013. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur. Respir. J. 41:1393-1400.
7. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF. 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 7:e30479. http://dx.doi.org/10.1371/journal.pone.0030479.
8. Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, Balasubramanian R, Selvakumar N, Ponnuraja C, Iliayas AS, Gangadevi NP, Raman B, Baskaran D, Kumar SR, Kumar MM, Mohan V, Ganapathy S, Kumar V, Shanmugam G, Charles N, Sakthivel MR, Jagannath K, Chandrasekar C, Parthasarathy RT, Narayanan PR. 2013. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 8:e67030. http://dx.doi.org/10.1371/journal.pone.0067030.
9. Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK. 2014. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob. Agents Chemother. 58:495-502. http://dx.doi.org/10.1128/AAC.01903- 13.
10. Krüüner A, Yates MD, Drobniewski FA. 2006. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:811-818. http://dx.doi.org/10.1128/JCM.44.3.811-818.2006.
11. Bactec. Bactec MGIT 960 SIRE kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. https://www.bd.com/ds/technicalCenter/ clsi/clsi-960sire.pdf.